Lisinopril/hydrochlorothiazide
Lisinopril (top) and hydrochlorothiazide (bottom)
Combination of
LisinoprilACE inhibitor
HydrochlorothiazideThiazide diuretic
Clinical data
Trade namesZestoretic, Prinzide, others
Other nameslisinopril/hctz
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa601070
License data
Pregnancy
category
  • Contraindicated
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG
  (verify)

Lisinopril/hydrochlorothiazide, sold under the brand name Zestoretic among others, is a fixed-dose combination medication used for the treatment of high blood pressure (hypertension).[1] It contains lisinopril, an ACE inhibitor, and hydrochlorothiazide, a diuretic.[1][2] Typically, it becomes an option once a person is doing well on the individual components.[3] It is taken by mouth.[2]

Common side effects include dizziness, headache, cough, and feeling tired.[1] Severe side effects may include angioedema and low blood pressure.[1] Use during pregnancy may harm the baby.[1]

The combination was approved for medical use in the United States in 1989.[2] It is on the World Health Organization's List of Essential Medicines.[4] It is available as a generic medication.[3] In 2021, it was the 51st most commonly prescribed medication in the United States, with more than 12 million prescriptions.[5][6]

Medical uses

Lisinopril/hydrochlorothiazide is indicated for the treatment of hypertension, to lower blood pressure.[1]

Adverse effects

The US Food and Drug Administration prescription label for the combination contains a boxed warning about harm to the baby.[1]

References

  1. 1 2 3 4 5 6 7 8 "Zestoretic- lisinopril and hydrochlorothiazide tablet". DailyMed. Retrieved 9 February 2022.
  2. 1 2 3 "Hydrochlorothiazide and lisinopril Uses, Side Effects & Warnings". Drugs.com. Cerner Multum. Retrieved 26 December 2018.
  3. 1 2 British national formulary : BNF 74 (74 ed.). British Medical Association. 2017. p. 166. ISBN 978-0857112989.
  4. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  5. ↑ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  6. ↑ "Hydrochlorothiazide; Lisinopril - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.